CSRXP APPLAUDS POSITIVE PROGRESS, ENCOURAGES POLICYMAKERS TO ADVANCE ADDITIONAL MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE
Policies Must Address Big Pharma’s Egregious Practices That Cause High Drug… Read More
Policies Must Address Big Pharma’s Egregious Practices That Cause High Drug… Read More
Comment Letters Highlight Key Agency Initiatives Targeting Brand Name Drug… Read More
Broad Majorities Reject Big Pharma’s Blame Game and Want Policymakers to… Read More
Brand Name Drug Companies Increase Prices on Treatments for Serious Conditions… Read More
Brand Name Drug Companies Continue Seeking to Price-Gouge COVID-19 Treatments… Read More
Brand Name Drug Companies Maintain Business-as-Usual Approach to Price-Gouging… Read More
Hemgenix Pricing Reflects Escalating Big Pharma Trend of Setting Higher and… Read More
Drug Company Sets Nearly $200,000 Price on Newly Approved Treatment for Type 1… Read More
Interchangeable Biosimilars Help Provide Patients with Greater Choice and More… Read More
Big Pharma Companies Want to Price-Gouge the American People and Health Care… Read More
Brand Name Drug Maker Amylyx Sets Price Tag For Relyvrio Between Five And 17… Read More
Lawmakers Must Put Patients First And Reject Bogus Big Pharma Rhetoric… Read More